Kevin C. Mannix | Teva Pharmaceutical Industries Ltd. |
Kåre Schultz | Teva Pharmaceutical Industries Ltd. |
Michael McClellan | Teva Pharmaceutical Industries Ltd. |
Brendan O'Grady | Teva Pharmaceutical Industries Ltd. |
Douglas Tsao | Barclays Capital, Inc. |
Louise Chen | Cantor Fitzgerald Securities |
Vamil K. Divan | Credit Suisse Securities (NYSE:USA) LLC |
Randall S. Stanicky | RBC Capital Markets LLC |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Liav Abraham | Citigroup Global Markets, Inc. |
Umer Raffat | Evercore Group LLC |
Jami Rubin | Goldman Sachs & Co. LLC |
Ken Cacciatore | Cowen & Co. LLC |
David Maris | Wells Fargo Securities LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Chris Schott | JPMorgan Securities LLC |
Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to the Fourth Quarter 2017 Financial Results. At this time, all participants are in a listen-only mode. There will be a presentation, followed by a question-and-answer session I must advise you this conference is being recorded today, Thursday, February 8, 2018. And I'd now like to hand the conference over to your speaker today, Kevin Mannix, Senior Vice President, Head of Investor Relations. Please go ahead.